|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Comparison of pre-treatment and post-treatment use of selenium in retinal ischemia reperfusion injury显示文摘AIM: To investigate the effects of selenium in rat retinal ischemia reperfusion(IR) model and compare pretreatment and post-treatment use.METHODS: Selenium pre-treatment group(n =8) was treated with intraperitoneal(i.p.) selenium 0.5 mg/kg for7 d and terminated 24 h after the IR injury. Selenium posttreatment group( n = 8) was treated with i. p. selenium0.5 mg/kg for 7d after the IR injury with termination at the end of the 7d period. Sham group(n =8) received i.p.saline injections identical to the selenium volume for 7d with termination 24 h after the IR injury. Control group(n =8) received no intervention. Main outcome measures were retina superoxide dismutase(SOD), glutathione(GSH),total antioxidant status(TAS), malondialdehyde(MDA),DNA fragmentation levels, and immunohistological apoptosis evaluation.RESULTS: Compared to the Sham group, selenium pre-treatment had a statistical difference in all parameters except SOD. Post-treatment selenium also resulted in statistical differences in all parameters except the MDA levels. When comparing selenium groups, the pre-treatment selenium group had a statistically higher success in reduction of markers of cell damage such as MDA and DNA fragmentation. In contrast, the post-selenium treatment group had resulted in statisticallyhigher levels of GSH. Histologically both selenium groups succeeded to limit retinal thickening and apoptosis. Pre-treatment use was statistically more successful in decreasing apoptosis in ganglion cell layer compared to post-treatment use.CONCLUSION: Selenium was successful in retinal protection in IR injuries. Pre-treatment efficacy was superior in terms of prevention of tissue damage and apoptosis. | Alper Yazici Hasan Aksit Esin Sogutlu Sari Arzu Yay Haydar Ali Erken Dilek Aksit Harun Cakmak Kamil Seyrek Sitki Samet Ermis | 2015 | International Journal of Ophthalmology(English edition)2015，8，2： | 3 |
| 2 | 新型经脉络膜上腔引流房水植入装置Suprajet的疗效观察(英文)显示文摘目的:评估一种由睫状体前和脉络膜上腔引流房水的新型植入装置Suprajet的有效性和安全性。方法:该项研究使用5只兔子。每只兔子的一眼植入Suprajet。引流器通过位于上方的透明角膜切口,经由前房置入脉络膜上腔。引流器近端位于睫状体根部,远端位于脉络膜上腔。兔子饲养、观察4wk。使用Tonopen AVIA测量术前和术后的眼压。最后一次随访观察时,兔子被牺牲处死,眼球摘除,进行大体上和组织学的观察评估。结果:术前眼压为18.6±6.1mmH g。术后1wk眼压为8.4±1.1mmH g。术后2wk 1只兔子死亡。因此,仅有4只兔子进行了后续观察。术后2wk眼压为11.0±2.8mmH g,术后3wk为9.50±3.1mmH g,术后4wk为11.3±3.3mmH g。与术前平均眼压相比,仅第1周的平均眼压显著降低(P=0.042),术后2wk、3wk和术后4wk的平均眼压无明显变化(P=0.66,P=0.66,P=0.102)。术中并发症包括3眼少量出血。术后2d出血已经完全吸收。对摘除眼球的大体观察发现,1眼中引流器的远端位于玻璃体内,而不是位于脉络膜上腔;其它3眼引流器的远端位于脉络膜上腔。所有眼中,近端都位于前房角。对摘除眼的组织学检查发现:不规则的胶原蛋白束和纤维沉积,包括引流器周围大量的成纤维细胞和组织细胞。结论:这一项初始动物研究显示,青光眼中Suprajet植入是一项有前景的术式。需要进行更进一步的研究以评估其有效性和安全性。 | Uzeyir Gunenc Gul Arikan Ferim Gunenc Banu Lebe Sitki Eren Elvan Ocmen Arif Taylan Ozturk | 2017 | 国际眼科杂志2017，17，10： | 2 |
| 3 | A Phase I Study of the Chinese Herbal Medicine PHY906 as a Modulator of Irinotecan-based Chemotherapy in Patients with Advanced Colorectal Cancer显示文摘 | Shivaani Kummar M. Sitki Copur Michal Rose Scott Wadler Joe Stephenson Mark O’Rourke Wayne Brenckman Robert Tilton Shwu-Huey Liu Zaoli Jiang Tahmun Su Yung-chi Cheng Edward Chu | 2011 | Clinical Colorectal Cancer2011，，2： | 1 |
| 4 | Safety and Efficacy of Panitumumab Therapy After Progression With Cetuximab: Experience at Two Institutions显示文摘 | Muhammad Wasif Saif Kristin Kaley Edward Chu M. Sitki Copur | 2010 | Clinical Colorectal Cancer2010，，5： | 1 |
| 5 | Producing 3D city model with the combined photogrammetric and laser scanner data in the example of Taksim Cumhuriyet square显示文摘 | Cumhur Sahin Ayhan Alkis Bahadir Ergun Sitki Kulur Fatmagul Batuk Ali Kilic | 2012 | Optics and Lasers in Engineering2012，，12： | 1 |
| 6 | Non-dipping pattern in untreated hypertensive patients is related to increased pulse wave velocity independent of raised nocturnal blood pressure显示文摘 | Yuksel Cicek Murtaza Emre Durakoglugil Sinan Altan Kocaman Mustafa Cetin Turan Erdogan Sitki Dogan Yavuz Ugurlu Aytun Canga | 2013 | Blood Pressure2013，，1： | 1 |
| 7 | Blood pressure and vascular reactivity to endothelin‐1, phenylephrine, serotonin, KCl and acetylcholine following chronic alcohol consumption in vitro显示文摘 | TijenUtkan FiruzanYildiz GülIlbay Sitki?zdemirci Bekir FarukErden NejatGacar GünerUlak | 2001 | Fundamental & Clinical Pharmacology2001，，3： | 1 |
| 8 | Biomarkers for Hepatocellular Carcinoma显示文摘 | Tara Behne M. Sitki Copur Neil Guha | 2012 | International Journal of Hepatology2012，，： | 1 |
| 9 | Modelling, on-line state estimation and fuzzy control of production scale fed-batch baker's yeast fermentationa显示文摘 | Cihan Karakuzua Mustafa Turker Sitki Ozturk | 2006 | Comrol Engineering Practice2006，14，： | 1 |
| 10 | Biology of epstein-barr virus during infectious mononucleosis显示文摘 | SITKI GREEN HOOD EDWARDS COVINGO M M | 2004 | Journal of Infectious Disease2004，189，4： | 1 |
| 11 | Determination of lead and nickel in environmental samples by flame atomic absorption spectrometry after column solid -phase extraction on Ambersorb -572 with EDTA显示文摘 | SITKI BAYTAK REHBER TURKER A | 2006 | Journal of Hazardous Materials2006，28，： | 1 |
| 12 | Biology of Epstein-Barr virus during infectious mononucleosis显示文摘 | Sitki Green Hood Edwards Covingo M | 2004 | J Infect Dis2004，189，4： | 1 |
| 13 | Coronary interventions with unfamiliar equipments显示文摘 | Ejder Kardesoglu Omer Uz Zafer Isllal Bekir Sitki Cebeci | 2010 | Chinese Medical Journal2010，，20： | 0 |
| 14 | Chidamide Combined with Paclitaxel Liposome for the Treatment of Advanced HER2-negative Breast Cancer in Clinical Study显示文摘The purpose of this study was to investigate the efficacy and safety of chidamide combined with paclitaxel liposome in the treatment of advanced HER-2-negative breast cancer.First,41 patients with advanced HER-2-negative breast cancer who had received two chemotherapy regimens from May 2017 to November 2017 were randomly selected to receive chidamide combined with paclitaxel liposome treatment(observation group,n=20)or placebo combined with paclitaxel liposome treatment(control group,n=21).The treatment scheme of the observation group was oral chidamide 30mg twice a week for 2 months.In addition,on day 1,the patients were given paclitaxel liposome orally and intravenously administered with 175 mg/m2 for 1 cycle for 21 days and 3 cycles of chemotherapy.The treatment scheme of the control group was oral placebo 30 mg twice a week for 2 months.In addition,the method of paclitaxel liposome administration was the same as the observation group.The response rate(RR),disease control rate(DCR),and progression-free survival(PFS)were compared between the two groups.The results showed that all the 41 patients could be evaluated.In the observation group,CR5,PR7,SD5 and PD3 were obtained.RR was 60.0%and DCR was 85.0%.In the control group,CR3,PR3,SD5 and PD10 were obtained.RR was 28.6%and DCR was 52.4%.RR and DCR in the observation group were better than those in the control group,and the difference was statistically significant(P<0.05).The median PFS of the observation group was 5.2 months,longer than that of the control group(3.1 months,P<0.05).The main adverse reactions in the two groups were gastrointestinal reactions and bone marrow suppression,with grade 1~2 as the main ones.The incidence of leukopenia,thrombocytopenia and nausea and vomiting in the observation group was higher than that in the control group(P<0.05).Therefore,the chidamide combined with paclitaxel liposome is effective in the treatment of advanced HER-2-negative breast cancer,and the adverse reactions can be tolerated. | Ichrak Ben Abdallah Mehmet Sitki Copur | 2019 | Advances in Modern Oncology Research2019，5，5： | 0 |
| 15 | CSCR中盐皮质激素受体基因-2G/C的多态性及其与血浆皮质醇水平的关系(英文)显示文摘目的:评估中心性浆液性脉络膜视网膜(CSCR)病变中盐皮质激素受体基因-2G/C单核苷酸多态性,以及基因多态性和血浆皮质醇水平的关系。方法:选取60例中心性浆液性脉络膜视网膜病变患者和50例正常人作为研究对象。患者皆患有急性中心性浆液性脉络膜视网膜病变,即浆液性视网膜脱离和视网膜色素上皮脱离或功能障碍(排除其它可能导致渗出的疾病,比如脉络膜新生血管、炎症或浸润病变)。为避免皮质醇水平的昼夜变化,上午8时到10时之间采集外周血样,检测盐皮质激素受体基因多态性(rs2070951)和血浆皮质醇水平。结果:CSCR组的基因型频率分布为G/C(46.6%),G/G(26.7%)和C/C(26.7%)。两组间基因型分布无统计学差异(P=0.96)。研究结果显示,CSCR组的血浆皮质醇水平为401.2±162.1 nmol/L,对照组为296.8±130.1nmol/L,两组间差异有统计学意义(P<0.01)。血浆皮质醇水平在G/C(345.0±137.0 nmol/L),G/G(369.2±165.3 nmol/L)和C/C(395.3±188.8 nmol/L)基因型之间不存在差异(P=0.50)。结论:盐皮质激素受体基因多态性与中心性浆液性脉络膜视网膜病变和血浆皮质醇水平无关。 | Alper Yazici Esin Sogutlu Sari Betul Eser Gozde Sahin Medine Alpdemir Adil Kilic Muhammet Kazim Erol Sitki Samet Ermis | 2016 | 国际眼科杂志2016，16，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员